Close

News and events

Latest blogs

Expert opinion

The global community is certainly in a very different place for this year’s World AIDS Day. We are facing the colliding impacts of two of the biggest epidemics of our time: HIV/AIDS and COVID-19.
Hydroxychloroquine was quickly thrown into a global spotlight after it garnered simultaneous praise and criticism from a number of high-profile sources.   The drug has since been investigated in several randomised clinical trials and observational studies. Most studies to date have shown no evidence of a benefit of hydroxychloroquine as a treatment for patients admitted to hospital who already have COVID-19.  
As I left the UN General Assembly High-Level Meeting on Ending TB in New York two years ago, there was renewed hope that this could be a turning point for accelerating progress against tuberculosis (TB). But COVID-19 has shifted global TB control from acceleration into reverse.
Also contributing to this opinion piece were: Sharifah Sekalala, Associate Professor at the University of Warwick; Judith Bueno de Mesquita, Co-Deputy Director at the Human Rights Centre, University of Essex; Claire Lougarre, Lecturer and Director of the Centre for Health Ethics and Law at the University of Southampton; and Michel Coleman, Professor of Epidemiology and Vital Statistics at the London School of Hygiene & Tropical Medicine.